ERBB2 and breast carcinoma: Among HER2-positive breast cancer patients showing HER2 loss from primary to recurrent breast cancer (n = 26), the great majority (n = 20, 77%) maintained some level of HER2 expression, exhibiting a HER2-low phenotype.